Cutia Therapeutics (HKSE:02487) Total Inventories: HK$39.2 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02487 Cutia Therapeutics HKSE:02487
40 GF Score
Price HK$2.61
GF Value HK$16.27
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Cutia Therapeutics Total Inventories?

Cutia Therapeutics HKSE:02487 +6.10% 40 Total Inventories is HK$39.2 Mil as of Dec. 2025. GuruFocus rates HKSE:02487 with a GF Score™ of 40/100 and a GF Value™ of HK$16.27 (Possible Value Trap). The stock has 4 warning signs investors should review.

Cutia Therapeutics's total inventories for the quarter that ended in Dec. 2025 was HK$39.2 Mil. Cutia Therapeutics's average total inventories from the quarter that ended in Jun. 2025 to the quarter that ended in Dec. 2025 was HK$54.1 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Cutia Therapeutics's Net-Net Working Capital per share for the quarter that ended in Dec. 2025 was HK$1.57.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Cutia Therapeutics's Days Inventory for the six months ended in Dec. 2025 was 84.28.

Inventory Turnover measures how fast the company turns over its inventory within a year. Cutia Therapeutics's Inventory Turnover for the quarter that ended in Dec. 2025 was 2.17.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Cutia Therapeutics's Inventory-to-Revenue for the quarter that ended in Dec. 2025 was 0.18.


Cutia Therapeutics  (HKSE:02487) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Cutia Therapeutics's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2025 is

Net-Net Working Capital Per Share (Q: Dec. 2025 )
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(870.79+0.75 * 194.411+0.5 * 39.178-465.084
-0-0)/363.368
=1.57

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Cutia Therapeutics's Days Inventory for the six months ended in Dec. 2025 is calculated as:

Days Inventory=Average Total Inventories (Q: Dec. 2025 )/Cost of Goods Sold (Q: Dec. 2025 )*Days in Period
=54.1495/117.25*365 / 2
=84.28

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Cutia Therapeutics's Inventory Turnover for the quarter that ended in Dec. 2025 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Dec. 2025 ) / Average Total Inventories (Q: Dec. 2025 )
=117.25 / 54.1495
=2.17

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Cutia Therapeutics's Inventory to Revenue for the quarter that ended in Dec. 2025 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Dec. 2025 ) / Revenue (Q: Dec. 2025 )
=54.1495 / 298.123
=0.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.


Cutia Therapeutics Total Inventories Related Terms


Cutia Therapeutics Total Inventories Historical Data

* Premium members only.

The historical data trend for Cutia Therapeutics's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cutia Therapeutics Total Inventories Chart

Cutia Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Total Inventories
2.21 22.33 49.56 79.75 39.18

Cutia Therapeutics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Inventories Get a 7-Day Free Trial Premium Member Only 49.56 69.68 79.75 69.12 39.18
HKSE:02487
40GF Score
Cutia Therapeutics HKSE:02487
Total Inventories is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cutia Therapeutics Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

Frequently Asked Questions Learn more about Total Inventories →
What does a Total Inventories of HK$39.2 Mil mean?
Cutia Therapeutics (HKSE:02487) has a Total Inventories of HK$39.2 Mil as of Dec. 2025. The total amount of inventory as recorded on a company's balance sheet. View historical data for Cutia Therapeutics and its competitors.
Is Cutia Therapeutics' Total Inventories too high?
Cutia Therapeutics' current Total Inventories is HK$39.2 Mil. Overall, Cutia Therapeutics has a GF Score™ of 40/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cutia Therapeutics' Total Inventories compare to VRTX and REGN?
Cutia Therapeutics' Total Inventories of HK$39.2 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Biotechnology company?
A good Total Inventories depends on the Biotechnology industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for Cutia Therapeutics and its competitors. Cutia Therapeutics's current Total Inventories is HK$39.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cutia Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Cutia Therapeutics (HKSE:02487) is currently considered Possible Value Trap. The stock's GF Value™ is HK$16.27, compared to a current price of HK$2.61 — trading 84% below its estimated fair value. The current Total Inventories is HK$39.2 Mil. Cutia Therapeutics' overall GF Score™ is 40/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For Cutia Therapeutics (HKSE:02487), the current Total Inventories is HK$39.2 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cutia Therapeutics (HKSE:02487) Overvalued in 2026?

Based on GuruFocus' analysis, Cutia Therapeutics stock appears to be undervalued. The current stock price of HK$2.61 is trading 84% below its estimated GF Value™ of HK$16.27. GuruFocus considers Cutia Therapeutics to be Possible Value Trap.

Key valuation signals for HKSE:02487:

  • Total Inventories: HK$39.2 Mil
  • GF Value™: HK$16.27 vs. price of HK$2.61 (84% below fair value)
  • GF Score™: 40/100 with 4 warning signs

No single metric tells the full story. See the HKSE:02487 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Cutia Therapeutics Business Description

Address 436 Heng Feng Road, 20th Floor, Huanzhi Building, Jingan District, Shanghai, CHN, 200070
Cutia Therapeutics is an investment holding company. The Company and its subsidiaries are principally engaged in developing inventive and comprehensive solutions that are tailored to meet the diverse and evolving needs of patients and consumers in the broader dermatology treatment and care market. It has a proprietary CATAME technology platform, which includes: Colloidal-Emulsification-Active Encapsulation (CEAE) platform, Aerosol (ARS) platform, Transdermal Delivery (TDD) platform, Actives & Formulation Evaluation (AFE) platform, Micro/Nano-Particulates & Self-Assembly (MiSA) platform, and Ex vivo & Efficacy Evaluation (EVEE) platform. It enables the development of a wide range of product dosage forms and the relevant formulation technology.
40GF Score

Get the complete analysis for HKSE:02487

Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$2.61
Price
HK$16.27
GF Value